

Lawrence Eichenfield

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3717130/publications.pdf>

Version: 2024-02-01

255
papers

19,178
citations

13865

67
h-index

12946

131
g-index

271
all docs

271
docs citations

271
times ranked

11315
citing authors

#	ARTICLE	IF	CITATIONS
1	Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2057-2062.	2.2	6
2	The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes: an expert panel consensus statement. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2397-2399.	2.2	4
3	Executive summary: Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 158-161.	1.2	1
4	American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1335-1336.e18.	1.2	54
5	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD _v): a clinical outcome measure for the severity of atopic dermatitis. <i>British Journal of Dermatology</i> , 2022, 187, 531-538.	1.5	13
6	Isotretinoin does not contribute to increased neuropsychiatric risk in the overall acne population, but risk management during treatment remains essential. <i>British Journal of Dermatology</i> , 2022, , .	1.5	2
7	Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset. <i>Dermatology and Therapy</i> , 2022, 12, 1337-1350.	3.0	3
8	Atopic dermatitis Review of comorbidities and therapeutics. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 142-149.	1.0	6
9	Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting. <i>Paediatric Drugs</i> , 2022, 24, 293-305.	3.1	16
10	Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP). <i>Italian Journal of Pediatrics</i> , 2022, 48, .	2.6	7
11	Isotretinoin and iPledge Program patient information video: A new modality that improves patient comprehension. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1425-1426.	1.2	1
12	Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1140-1142.	1.2	8
13	Medical algorithm: Treatment of atopic dermatitis in early childhood (part II). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 407-410.	5.7	4
14	Characteristics of nonmelanoma skin cancer in children without identifiable risk factors. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1472-1476.	1.2	1
15	A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient Education Network in Dermatology (OPENED) task force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 787-796.	2.4	30
16	Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database. <i>Pediatric Dermatology</i> , 2021, 38, 119-124.	0.9	17
17	Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. <i>Pediatric Dermatology</i> , 2021, 38, 164-180.	0.9	34
18	Medical algorithm: Diagnosis of atopic dermatitis in early childhood (part I). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 403-406.	5.7	6

#	ARTICLE	IF	CITATIONS
19	Dupilumab provides favourable long-term safety and efficacy in children aged 6 to ≤ 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. <i>British Journal of Dermatology</i> , 2021, 184, 857-870.	1.5	45
20	Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome. <i>JAMA Dermatology</i> , 2021, 157, 98.	4.1	31
21	Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 257-265.	6.7	5
22	Management of Severe Atopic Dermatitis in Pediatric Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1462-1471.	3.8	16
23	Hidradenitis Suppurativa in the Pediatric Population. <i>JAMA Dermatology</i> , 2021, 157, 385.	4.1	36
24	Topical therapy of atopic dermatitis with a focus on pimecrolimus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1505-1518.	2.4	15
25	Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria. <i>British Journal of Dermatology</i> , 2021, 185, 447-449.	1.5	10
26	Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council. <i>JAAD International</i> , 2021, 3, 8-13.	2.2	8
27	Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2021, 157, 1165.	4.1	79
28	Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 863-872.	1.2	151
29	A retrospective analysis of diagnostic testing in a large North American cohort of patients with epidermolysis bullosa. <i>Journal of the American Academy of Dermatology</i> , 2021, . .	1.2	3
30	Management of Acne Vulgaris. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2055.	7.4	116
31	Not COVID Toes: Pool Palms and Feet in Pediatric Patients. , 2021, 108, 276-295.		0
32	Safety and Efficacy of VP-102 (Cantharidin, 0.7% w/v) in Molluscum Contagiosum by Body Region: Pooled Analyses from Two Phase III Randomized Trials.. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2021, 14, 42-47.	0.1	3
33	Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase II a open-label trial and subsequent phase III open-label extension. <i>British Journal of Dermatology</i> , 2020, 182, 85-96.	1.5	111
34	Long-term safety and efficacy of trifarotene 0.05% cream, a first-in-class RAR β selective topical retinoid, in patients with moderate facial and truncal acne. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 166-173.	2.4	46
35	TREATment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. <i>British Journal of Dermatology</i> , 2020, 182, 1423-1429.	1.5	14
36	Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1098-1104.	2.4	3

#	ARTICLE	IF	CITATIONS
37	The impact of airborne pollution on atopic dermatitis: a literature review. <i>British Journal of Dermatology</i> , 2020, 183, 16-23.	1.5	54
38	Diaper dermatitis prevalence and severity: Global perspective on the impact of caregiver behavior. <i>Pediatric Dermatology</i> , 2020, 37, 130-136.	0.9	34
39	Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis. <i>Pediatric Dermatology</i> , 2020, 37, 1030-1037.	0.9	5
40	Multidisciplinary care of epidermolysis bullosa during the COVID-19 pandemic—Consensus: Recommendations by an international panel of experts. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1222-1224.	1.2	7
41	Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 1333.	4.1	194
42	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020, 10, e039928.	1.9	8
43	Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With <i>Molluscum Contagiosum</i> . <i>JAMA Dermatology</i> , 2020, 156, 1315.	4.1	19
44	Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (â‰¥ 6 to <lt>Tj ETQq0 0 0 rgBT /Ove</sc> <sc>CADMUS</sc> Jr study. <i>British Journal of Dermatology</i> , 2020, 183, 664-672.	1.5	53
45	Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database. <i>Dermatology and Therapy</i> , 2020, 10, 791-806.	3.0	22
46	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 411.	4.1	241
47	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<sc>III</sc> trials. <i>British Journal of Dermatology</i> , 2020, 183, 242-255.	1.5	277
48	Skin cleansing and topical product use in patients with epidermolysis bullosa: Results from a multicenter database. <i>Pediatric Dermatology</i> , 2020, 37, 326-332.	0.9	9
49	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 839-846.	1.2	78
50	Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 477-485.	1.2	23
51	Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic. <i>Pediatric Dermatology</i> , 2020, 37, 424-434.	0.9	11
52	Update on Pediatric Atopic Dermatitis. , 2020, 106, 143-146.		9
53	<sc>TREAT</sc> atment of <sc>AT</sc> opic eczema (<sc>TREAT</sc>) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photoand systemic therapy registries. <i>British Journal of Dermatology</i> , 2019, 180, 790-801.	1.5	26
54	Recurrent herpes labialis in the pediatric population: Prevalence, therapeutic studies, and associated complications. <i>Pediatric Dermatology</i> , 2019, 36, 808-814.	0.9	7

#	ARTICLE	IF	CITATIONS
55	Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 42.	1.9	36
56	Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in a preadolescent population. <i>Pediatric Dermatology</i> , 2019, 36, 193-199.	0.9	12
57	Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis. <i>Pediatric Dermatology</i> , 2019, 36, 172-176.	0.9	24
58	<sc>TREAT</sc> atment of <sc>AT</sc> opic eczema (<sc>TREAT</sc>) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. <i>British Journal of Dermatology</i> , 2019, 181, 492-504.	1.5	29
59	The microbiome in preadolescent acne: Assessment and prospective analysis of the influence of benzoyl peroxide. <i>Pediatric Dermatology</i> , 2019, 36, 200-206.	0.9	17
60	Atypical Café-au-Lait Macules in a Patient with Koolen-De Vries Syndrome (17q21.31 Microdeletion) <i>Tj ETQq, 0, 0 rgBT /Overlock</i>	0.9	1
61	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 443-456.	6.7	130
62	Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children and Young Adults. <i>Journal of Pediatrics</i> , 2019, 211, 152-158.	1.8	21
63	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1224-1231.	2.4	50
64	Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America. <i>JAMA Dermatology</i> , 2019, 155, 196.	4.1	27
65	Atopic Dermatitis. <i>Dermatologic Clinics</i> , 2019, 37, 11-20.	1.7	33
66	Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1.0% for persistent erythema of rosacea in a phase IV study. <i>British Journal of Dermatology</i> , 2019, 180, 1050-1057.	1.5	10
67	Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1305-1313.	2.4	24
68	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2018, 178, e332-e341.	1.5	96
69	Atopic Dermatitis. <i>Pediatrics in Review</i> , 2018, 39, 180-193.	0.4	42
70	Developing drugs for treatment of atopic dermatitis in children (3 months to <18 years of age): Draft guidance for industry. <i>Pediatric Dermatology</i> , 2018, 35, 303-322.	0.9	16
71	Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 863-871.e11.	1.2	267
72	Emerging therapies for atopic dermatitis: JAK inhibitors. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, S53-S62.	1.2	88

#	ARTICLE	IF	CITATIONS
73	Analyzing the Genetic Spectrum of Vascular Anomalies with Overgrowth via Cancer Genomics. <i>Journal of Investigative Dermatology</i> , 2018, 138, 957-967.	0.7	45
74	Pediatric psoriasis: Evolving perspectives. <i>Pediatric Dermatology</i> , 2018, 35, 170-181.	0.9	66
75	Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. <i>Dermatology and Therapy</i> , 2018, 8, 605-619.	3.0	18
76	Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 821-838.	6.7	159
77	Primary cutaneous aspergillosis at the site of cyanoacrylate skin adhesive in a neonate. <i>Pediatric Dermatology</i> , 2018, 35, 494-497.	0.9	5
78	Transforming acne care by pediatricians: An interventional cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 966-968.	1.2	2
79	Recent advances in understanding and preventing peanut and tree nut hypersensitivity. <i>F1000Research</i> , 2018, 7, 1716.	1.6	4
80	Altered proliferation and networks in neural cells derived from idiopathic autistic individuals. <i>Molecular Psychiatry</i> , 2017, 22, 820-835.	7.9	349
81	Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 29-44.	2.9	374
82	Acne and Rosacea. <i>Dermatology and Therapy</i> , 2017, 7, 43-52.	3.0	52
83	Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored Expert Panel. <i>Journal of Pediatric Nursing</i> , 2017, 32, 91-98.	1.5	14
84	Addendum Guidelines for the Prevention of Peanut Allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored Expert Panel. <i>Pediatric Dermatology</i> , 2017, 34, e1-e21.	0.9	20
85	Addendum guidelines for the prevention of peanut allergy in the United States. <i>Pediatric Dermatology</i> , 2017, 34, 5-12.	0.9	17
86	Optimizing Clinical Trials for Atopic Dermatitis in Children. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1363-1364.	0.7	4
87	Phenotypic spectrum of autosomal recessive congenital ichthyosis due to <i>PNPLA1</i> mutation. <i>British Journal of Dermatology</i> , 2017, 177, 319-322.	1.5	19
88	The Benefits of New Guidelines to Prevent Peanut Allergy. <i>Pediatrics</i> , 2017, 139, e20164293.	2.1	10
89	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1713-1719.	5.7	52
90	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 290-298.	1.2	137

#	ARTICLE	IF	CITATIONS
91	Pediatric Psoriasis Comorbidity Screening Guidelines. JAMA Dermatology, 2017, 153, 698.	4.1	84
92	Evidence-based recommendations for the management of acne fulminans and its variants. Journal of the American Academy of Dermatology, 2017, 77, 109-117.	1.2	64
93	Current and emerging topical therapies for atopic dermatitis. Clinics in Dermatology, 2017, 35, 375-382.	1.6	21
94	Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. Journal of Allergy and Clinical Immunology, 2017, 139, S49-S57.	2.9	165
95	Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Annals of Allergy, Asthma and Immunology, 2017, 118, 166-173.e7.	1.0	59
96	Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1519-1531.	3.8	141
97	Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. Journal of the American Academy of Dermatology, 2017, 77, 641-649.e5.	1.2	110
98	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 2017, 77, 623-633.	1.2	170
99	Current guidelines for the evaluation and management of atopic dermatitis – A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology Guidelines. Alergologia Polska - Polish Journal of Allergology, 2017, 4, 158-168.	0.0	8
100	Isotretinoin and Timing of Procedural Interventions. JAMA Dermatology, 2017, 153, 802.	4.1	93
101	Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook. Drugs, 2017, 77, 1389-1397.	10.9	31
102	Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Allergy, Asthma and Clinical Immunology, 2017, 13, .	2.0	11
103	Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. World Allergy Organization Journal, 2017, 10, 1.	3.5	48
104	Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. Journal of the American Academy of Dermatology, 2017, 76, 281-285.	1.2	73
105	Epidemiologic Analysis of Onychomycosis in the San Diego Pediatric Population. Pediatric Dermatology, 2017, 34, 46-49.	0.9	27
106	Practical Strategies for the Diagnosis and Assessment of Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S36-S38.	1.6	8
107	Atopic Dermatitis Progression: Evaluating Intervention Strategies. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S39-S41.	1.6	1
108	Nonpharmacologic Strategies and Topical Agents for Treating Atopic Dermatitis: An Update. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S42-S44.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Addressing the Immunopathogenesis of Atopic Dermatitis: Advances in Topical and Systemic Treatment. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S45-S48.	1.6	7
110	Atopic dermatitis: emerging therapies. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 124-130.	1.6	7
111	Atopic dermatitis: therapeutic care delivery: therapeutic education, shared decision-making, and access to care. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 131-136.	1.6	16
112	Atopic dermatitis: skin care and topical therapies. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 104-110.	1.6	8
113	Atopic dermatitis: pathogenesis. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 100-103.	1.6	59
114	Ocular Manifestations of Dermatologic Diseases. , 2017, , 197-239.		0
115	Meeting the Challenge of Atopic Dermatitis From Infancy to Adulthood. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S35-S35.	1.6	0
116	Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar. Seminars in Cutaneous Medicine and Surgery, 2017, 36, S52-S59.	1.6	0
117	Curriculum United for Better Eczema Care: why, how, and what?. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 93-94.	1.6	1
118	Emerging Issues in Adult Female Acne. Journal of Clinical and Aesthetic Dermatology, 2017, 10, 37-46.	0.1	17
119	Pediatric Onychomycosis: The Emerging Role of Topical Therapy. Journal of Drugs in Dermatology, 2017, 16, 105-109.	0.8	11
120	Study of the Atopic March: Development of Atopic Comorbidities. Pediatric Dermatology, 2016, 33, 388-398.	0.9	99
121	EB, or Not EB? Neonatal Desquamative Impetigo in a Degloving Pattern. Pediatric Dermatology, 2016, 33, e147-8.	0.9	4
122	Filling in Pediatric Acne Practice Gaps: A Prospective Multicenter Study of Case-Based Education. Journal of Adolescent Health, 2016, 59, 549-554.	2.5	4
123	High-dose isotretinoin: Bigger dents in wallets?. Journal of the American Academy of Dermatology, 2016, 75, e75-e76.	1.2	0
124	Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. Journal of the American Academy of Dermatology, 2016, 75, 494-503.e6.	1.2	425
125	Photodynamic therapy with methyl aminolaevulinate 80 mg g ⁻¹ for severe facial acne vulgaris: a randomized vehicle-controlled study. British Journal of Dermatology, 2016, 174, 770-777.	1.5	32
126	OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology, 2016, 75, 297-305.	1.2	88

#	ARTICLE	IF	CITATIONS
127	Consensus Conference on Clinical Management of pediatric Atopic Dermatitis. Italian Journal of Pediatrics, 2016, 42, 26.	2.6	67
128	Debates in allergy medicine: Specific immunotherapy in children with atopic dermatitis, the "œcon"œview. World Allergy Organization Journal, 2016, 9, 16.	3.5	7
129	Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split-body randomized controlled trial. British Journal of Dermatology, 2016, 175, 212-214.	1.5	43
130	Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile. Journal of Investigative Dermatology, 2016, 136, 67-73.	0.7	38
131	Update on Epidemiology, Diagnosis, and Disease Course of Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2016, 35, S84-S88.	1.6	38
132	Review of Critical Issues in the Pathogenesis of Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2016, 35, S89-91.	1.6	10
133	Assessing the New and Emerging Treatments for Atopic Dermatitis. Seminars in Cutaneous Medicine and Surgery, 2016, 35, S92-S96.	1.6	14
134	Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 1: Antibiotic Prescribing Patterns, Sources of Antibiotic Exposure, Antibiotic Consumption and Emergence of Antibiotic Resistance, Impact of Alterations in Antibiotic Prescribing, and Clinical Sequelae of Antibiotic Use. Journal of Clinical and Aesthetic Dermatology, 2016, 9, 18-24.	0.1	14
135	Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 3: Current Perspectives on Skin and Soft Tissue Infections with Emphasis on Methicillin-resistant Staphylococcus aureus, Commonly Encountered Scenarios when Antibiotic Use May Not Be Needed, and Concluding Remarks on Rational Use of Antibiotics in Dermatology. Journal of Clinical and Aesthetic Dermatology, 2016, 9, 17-24.	0.1	9
136	Religious Allergic Contact Dermatitis. Pediatric Dermatology, 2015, 32, e191-2.	0.9	2
137	Profile of clindamycin phosphate 1.2%/benzoyl peroxide 3.75% aqueous gel for the treatment of acne vulgaris. Clinical, Cosmetic and Investigational Dermatology, 2015, 8, 549.	1.8	4
138	Atopic dermatitis: Kids are not just little people. Clinics in Dermatology, 2015, 33, 594-604.	1.6	5
139	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 2015, 26, 306-315.	2.6	71
140	The Utility of Cantharidin for the Treatment of Molluscum Contagiosum. Pediatric Dermatology, 2015, 32, 295-295.	0.9	9
141	Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. Journal of Allergy and Clinical Immunology, 2015, 136, 258-261.	2.9	162
142	An Update on Pediatric Atopic Dermatitis and Food Allergies. Journal of Pediatrics, 2015, 167, 752-756.	1.8	13
143	Safety and Efficacy of Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in the Treatment of Extensive Scalp Psoriasis in Adolescents Ages 12 to 17 Years. Pediatric Dermatology, 2015, 32, 28-35.	0.9	20
144	Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants. Pediatrics, 2015, 136, 600-604.	2.1	23

#	ARTICLE	IF	CITATIONS
145	Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers. <i>Pediatrics</i> , 2015, 136, 554-565.	2.1	78
146	Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 594-603.	1.2	187
147	Food Allergy in Infants With Atopic Dermatitis: Limitations of Food-Specific IgE Measurements. <i>Pediatrics</i> , 2015, 136, e1530-e1538.	2.1	55
148	Adolescent Scalp Psoriasis: Update on Topical Combination Therapy. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, 43-7.	0.1	4
149	Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 1: overview, clinical characteristics, and laboratory evaluation. <i>Cutis</i> , 2015, 96, 236-41.	0.3	4
150	Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 2: topical therapies. <i>Cutis</i> , 2015, 96, 321-5.	0.3	5
151	Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 3: oral therapies. <i>Cutis</i> , 2015, 96, 376-82.	0.3	6
152	Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. <i>Human Molecular Genetics</i> , 2014, 23, 397-407.	2.9	112
153	A 6-Day-Old Male Infant With Linear Band of Skin-Colored Papules. <i>JAMA Pediatrics</i> , 2014, 168, 859.	6.2	3
154	Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). <i>British Journal of Dermatology</i> , 2014, 171, 1318-1325.	1.5	95
155	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 327-349.	1.2	695
156	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 116-132.	1.2	970
157	Optimizing outcomes for paediatric atopic dermatitis. <i>British Journal of Dermatology</i> , 2014, 170, 31-37.	1.5	27
158	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 338-351.	1.2	889
159	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1218-1233.	1.2	256
160	Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: a status report on physical modalities and devices. <i>Cutis</i> , 2014, 93, 71-6.	0.3	38
161	Therapeutic Patient Education in Children with Atopic Dermatitis: Position Paper on Objectives and Recommendations. <i>Pediatric Dermatology</i> , 2013, 30, 199-206.	0.9	60
162	Evidence-Based Recommendations for the Diagnosis and Treatment of Pediatric Acne. <i>Pediatrics</i> , 2013, 131, S163-S186.	2.1	192

#	ARTICLE	IF	CITATIONS
163	Infantile Hemangiomas: An Update on Pathogenesis and Therapy. <i>Pediatrics</i> , 2013, 131, 99-108.	2.1	162
164	Therapeutic Patient Education in Atopic Dermatitis: Worldwide Experiences. <i>Pediatric Dermatology</i> , 2013, 30, 329-334.	0.9	75
165	Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene-benzoyl peroxides. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 611-8.	0.8	17
166	Effect of cat and daycare exposures on the risk of asthma in children with atopic dermatitis. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 282-288.	2.2	26
167	Tretinoin Microsphere Gel 0.04% Pump for Treating Acne Vulgaris in Preadolescents: A Randomized, Controlled Study. <i>Pediatric Dermatology</i> , 2012, 29, 598-604.	0.9	10
168	Atopic Dermatitis: Epidemiology and Pathogenesis Update. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, S3-S5.	1.6	60
169	Understanding and Managing Atopic Dermatitis in Adult Patients. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, S18-S22.	1.6	57
170	Current Issues in Atopic Comorbidities and Preventing the Atopic March. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, S6-S9.	1.6	19
171	Perspectives in Atopic Dermatitis-Optimizing Outcomes: Introduction. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, S1-S2.	1.6	0
172	Consensus Guidelines for the Management of Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 95.	1.4	148
173	Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 818-24.	0.8	6
174	Pediatric "STUMP" lesions: Evaluation and management of difficult atypical Spitzoid lesions in children. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 559-572.	1.2	58
175	Effective monitoring of isotretinoin safety in a pediatric dermatology population: A novel patient symptom survey approach. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 517-524.	1.2	20
176	Contact sensitization in very young children. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 772-779.	1.2	75
177	Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 175-192.	1.2	67
178	The Acne Continuum: An Age-Based Approach to Therapy. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2011, 30, S6-S11.	1.6	28
179	Approach to Pediatric Acne Treatment: An Update. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2011, 30, S16-S21.	1.6	7
180	Introduction. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2011, 30, S1.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Children with Atopic Dermatitis Appear Less Likely to Be Infected with Community Acquired Methicillinâ€Resistant <i>Staphylococcus aureus</i>: The San Diego Experience. <i>Pediatric Dermatology</i> , 2011, 28, 6-11.	0.9	46
182	Acne in children. , 2011, , 182-197.		1
183	Safety and efficacy of clindamycin phosphate 1.2%-benzoyl peroxide 3% fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study. <i>Journal of Drugs in Dermatology</i> , 2011, 10, 1382-96.	0.8	23
184	The Safety and Efficacy of Tacrolimus Ointment in Pediatric Patients with Atopic Dermatitis. <i>Pediatric Dermatology</i> , 2010, 27, 425-436.	0.9	44
185	Study of the Efficacy and Tolerability of 0.04% Tretinoin Microsphere Gel for Preadolescent Acne. <i>Pediatrics</i> , 2010, 125, e1316-e1323.	2.1	17
186	Guidelines for the Diagnosis and Management of Food Allergy in the United States: Report of the NIAID-Sponsored Expert Panel. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, S1-S58.	2.9	1,149
187	Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1105-1118.	2.9	1,614
188	Intermittent etanercept therapy in pediatric patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 769-774.	1.2	42
189	Long-term etanercept in pediatric patients with plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 762-768.	1.2	96
190	Acne Epidemiology and Pathophysiology. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 2-4.	1.6	53
191	Diagnosis and Evaluation of Acne. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 5-8.	1.6	3
192	Perspectives on Therapeutic Options for Acne: An Update. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 13-16.	1.6	9
193	Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. <i>Journal of Drugs in Dermatology</i> , 2010, 9, 33-40.	0.8	18
194	Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled, double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. <i>Cutis</i> , 2010, 85, 94-104.	0.3	38
195	Fluocinolone Acetonide 0.01% in Peanut Oil: Safety and Efficacy Data in the Treatment of Childhood Atopic Dermatitis in Infants as Young as 3â€fMonths of Age. <i>Pediatric Dermatology</i> , 2009, 26, 262-268.	0.9	15
196	A Novel Gel Formulation of 0.25% Tretinoin and 1.2% Clindamycin Phosphate: Efficacy in Acne Vulgaris Patients Aged 12 to 18 Years. <i>Pediatric Dermatology</i> , 2009, 26, 257-261.	0.9	20
197	Quantitative Assessment of Combination Bathing and Moisturizing Regimens on Skin Hydration in Atopic Dermatitis. <i>Pediatric Dermatology</i> , 2009, 26, 273-278.	0.9	72
198	The Benefits of Sunflower Oleodistillate (SOD) in Pediatric Dermatology. <i>Pediatric Dermatology</i> , 2009, 26, 669-675.	0.9	56

#	ARTICLE	IF	CITATIONS
199	Practical Considerations in Acne Treatment and the Clinical Impact of Topical Combination Therapy. <i>Pediatric Dermatology</i> , 2008, 25, 1-14.	0.9	156
200	MAS063DP is Effective Monotherapy for Mild to Moderate Atopic Dermatitis in Infants and Children: A Multicenter, Randomized, Vehicle-Controlled Study. <i>Journal of Pediatrics</i> , 2008, 152, 854-859.	1.8	74
201	Etanercept Treatment for Children and Adolescents with Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2008, 358, 241-251.	27.0	366
202	Three Times Weekly Tacrolimus Ointment Reduces Relapse in Stabilized Atopic Dermatitis: A New Paradigm for Use. <i>Pediatrics</i> , 2008, 122, e1210-e1218.	2.1	72
203	Management of Atopic Dermatitis in the Pediatric Population. <i>Pediatrics</i> , 2008, 122, 812-824.	2.1	176
204	Phase 4 study to assess tretinoin pump for the treatment of facial acne. <i>Journal of Drugs in Dermatology</i> , 2008, 7, 1129-36.	0.8	13
205	Clinical Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) in Paediatric Patients. <i>Dermatology</i> , 2007, 215, 3-17.	2.1	30
206	Treatment of ichthyosiform diseases with topically applied tazarotene: Risk of systemic absorption. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, S123-S125.	1.2	16
207	Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 791-799.	1.2	161
208	A systematic review of the safety of topical therapies for atopic dermatitis. <i>British Journal of Dermatology</i> , 2007, 156, 203-221.	1.5	171
209	Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis. <i>Journal of Dermatology</i> , 2007, 34, 231-236.	1.2	18
210	Evaluation of Adrenal Suppression of a Lipid Enhanced, Topical Emollient Cream Formulation of Hydrocortisone Butyrate 0.1% in Treating Children with Atopic Dermatitis. <i>Pediatric Dermatology</i> , 2007, 24, 81-84.	0.9	10
211	Effect of Desonide Hydrogel 0.05% on the Hypothalamic-Pituitary-Adrenal Axis in Pediatric Subjects with Moderate to Severe Atopic Dermatitis. <i>Pediatric Dermatology</i> , 2007, 24, 289-295.	0.9	32
212	Pediatric acne: clinical presentations, evaluation, and management. <i>Journal of Drugs in Dermatology</i> , 2007, 6, 589-93.	0.8	16
213	Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. <i>Journal of Drugs in Dermatology</i> , 2007, 6, 607-15.	0.8	46
214	Absorption and efficacy of miconazole nitrate 0.25% ointment in infants with diaper dermatitis. <i>Journal of Drugs in Dermatology</i> , 2007, 6, 522-6.	0.8	11
215	Natural advances in eczema care. <i>Cutis</i> , 2007, 80, 2-16.	0.3	15
216	The epidemiology of molluscum contagiosum in children. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 47-54.	1.2	153

#	ARTICLE	IF	CITATIONS
217	Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 715-717.	1.2	20
218	Periorificial dermatitis in children and adolescents. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 781-785.	1.2	77
219	Congenital localized scleroderma. <i>Journal of Pediatrics</i> , 2006, 149, 248-251.	1.8	50
220	Evolving management of atopic dermatitis. <i>Expert Review of Dermatology</i> , 2006, 1, 31-41.	0.3	1
221	A Practical Approach for the Use of Oral Isotretinoin for Infantile Acne. <i>Pediatric Dermatology</i> , 2005, 22, 166-169.	0.9	46
222	Pulmonary Thromboembolism Associated With Klippel-Trenaunay Syndrome. <i>Pediatrics</i> , 2005, 116, e596-e600.	2.1	87
223	Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, S186-S194.	1.2	125
224	Acne and your pediatric patient: a roundtable discussion of treatment modalities and other factors. <i>Cutis</i> , 2005, 76, 5-24.	0.3	10
225	Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. <i>British Journal of Dermatology</i> , 2004, 150, 96-102.	1.5	136
226	Disseminated linear calcinosis cutis associated with the Koebner phenomenon in an infant with congenital acute monocytic leukaemia. <i>British Journal of Dermatology</i> , 2004, 150, 753-756.	1.5	12
227	Validating outdoor workers' self-report of sun protection. <i>Preventive Medicine</i> , 2004, 39, 798-803.	3.4	69
228	Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 709-717.	1.2	50
229	Unique approaches for the topical treatment and prevention of cutaneous infections: report from a clinical roundtable. <i>Cutis</i> , 2004, 74, 2-23.	0.3	1
230	Genetic Heterogeneity in Erythrokeratoderma Variabilis: Novel Mutations in the Connexin Gene GJB4 (Cx30.3) and Genotype-Phenotype Correlations. <i>Journal of Investigative Dermatology</i> , 2003, 120, 601-609.	0.7	112
231	Current management of atopic dermatitis and interruption of the atopic march. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, S140-S150.	2.9	67
232	Consensus conference on pediatric atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 1088-1095.	1.2	226
233	Fluocinolone acetonide 0.01% in peanut oil: Therapy for childhood atopic dermatitis, even in patients who are peanut sensitive. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 569-577.	1.2	35
234	Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 1153-1168.	2.9	62

#	ARTICLE	IF	CITATIONS
235	Atopic Dermatitis and Asthma: Parallels in the Evolution of Treatment. <i>Pediatrics</i> , 2003, 111, 608-616.	2.1	187
236	Identifying Potential Regulators of Infantile Hemangioma Progression through Large-scale Expression Analysis: A Possible Role for the Immune System and Indoleamine 2,3 Dioxygenase (IDO) during Involution. <i>Lymphatic Research and Biology</i> , 2003, 1, 291-299.	1.1	43
237	Long-term safety of tacrolimus ointment in children treated for atopic dermatitis. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 457-465.	2.4	11
238	A Clinical Study to Evaluate the Efficacy of ELA-Max (4% Liposomal Lidocaine) as Compared With Eutectic Mixture of Local Anesthetics Cream for Pain Reduction of Venipuncture in Children. <i>Pediatrics</i> , 2002, 109, 1093-1099.	2.1	224
239	Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 495-504.	1.2	330
240	Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 562-570.	1.2	108
241	Promoting Sun Safety among Zoo Visitors. <i>Preventive Medicine</i> , 2001, 33, 162-169.	3.4	41
242	A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, S47-S57.	1.2	278
243	Compliance with federal and state legislation by indoor tanning facilities in San Diego. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 53-60.	1.2	67
244	Pediatric Anesthesia in Dermatologic Surgery: When Hand-Holding is Not Enough. <i>Dermatologic Surgery</i> , 2001, 27, 1010-1018.	0.8	50
245	Subcutaneous Infusion Anesthesia for Dermatologic Surgery in Children: Are We Ready?. <i>Pediatric Dermatology</i> , 2001, 18, 532-533.	0.9	5
246	A Prospective Comparison of Octyl Cyanoacrylate Tissue Adhesive (Dermabond) and Suture for the Closure of Excisional Wounds in Children and Adolescents. <i>Archives of Dermatology</i> , 2001, 137, 1177-80.	1.4	98
247	A national survey of sun safety activities at U.S. zoos. <i>Journal of Community Health</i> , 2000, 25, 331-342.	3.8	3
248	VASCULAR AND PIGMENTED BIRTHMARKS. <i>Pediatric Clinics of North America</i> , 2000, 47, 783-812.	1.8	47
249	Use of the Cotton Swab Method in Diagnosing Tinea Capitis. <i>Pediatrics</i> , 1999, 104, 276-279.	2.1	51
250	Cranial Fasciitis of Childhood. <i>Pediatric Dermatology</i> , 1999, 16, 232-234.	0.9	23
251	Guidelines of care for hemangiomas of infancy. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 631-637.	1.2	220
252	Vesiculopustular Eruption of Crohn's Disease. <i>Pediatric Dermatology</i> , 1996, 13, 127-130.	0.9	13

#	ARTICLE	IF	CITATIONS
253	Cutaneous telangiectases in neonatal lupus erythematosus. Journal of the American Academy of Dermatology, 1995, 33, 19-25.	1.2	65
254	Female infant with oncocytic cardiomyopathy and microphthalmia with linear skin defects (MLS): A clue to the pathogenesis of oncocytic cardiomyopathy?. American Journal of Medical Genetics Part A, 1994, 53, 141-148.	2.4	69
255	Laser treatment of vascular lesions in children: biologic/laser interactions. , 0, , .		0